Obesity Considerations in Pediatric Drug Development, 2016–2021

Abstract

Pediatric obesity is a global public health concern. Obesity‐related physiological changes may affect the pharmacokinetics of drugs and lead to therapeutic failure or toxicities. An earlier review of pediatric drug development programs from 2007 to 2016 found that, of 89 programs listing obesity‐related terms, only 4 (4%) products described pharmacokinetic changes associated with obesity. This review examined obesity considerations for 185 drug products for which pediatric drug development programs were submitted to the US Food and Drug Administration (FDA) between 2016 and 2021. The FDA‐authored review documents and drug product labeling were queried for obesity‐related terms and the review found 97/185 (52%) drug products had obesity‐related terms in these sources. Of the 97 drug products, 55/97 (57%) had obesity‐related terms in the FDA‐authored reviews only, 13/97 (13%) had obesity‐related terms in the drug product labeling only, and 29/97 (30%) had obesity‐related terms in both FDA‐authored reviews and drug product labeling. Most of the obesity‐related information in the drug product labeling originated from data collected from adults. Only 13/185 (7%) drug product labeling contained obesity‐related terms in reference to drug pharmacokinetics. Specific dosage recommendations for the use of the drug products in pediatric patients who are obese remain lacking. The dearth of available information to guide drug dosages in the obese pediatric population suggests that further research, innovative approaches, and evidence‐based guidelines are needed to inform the optimal therapeutic use of drugs in this population.